Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Alliance Grants

Ryerson University

$30,000.00

Portable Raman Analyzer for point-of-care rapid analysis of COVID-19 antibody

FY 2021-22

Summary
Rapid diagnosis of COVID-19 infection is critical for the prevention of disease spread. Our research team developed a point-of-care kit, QT100DxTM, which provides test result 2 minutes after sample preparation and can be used by non-technical personal in a non-lab setting, particularly suitable for mass screening at congregated settings. The kit analyzes both unprocessed raw saliva and blood plasma. The QT100Dx simultaneously detects multiple key essential biomarkers involved in constructing the absolute virus and immune response signals (antibodies) rising in patients due to COVID-19 infection from a very minimal salivary sample of 10 ul. The kit detection sensitivity up to 20 viral particles in 1 ml of saliva and 20 ng antibody per mL of blood plasma, far superior to popular PCR assays. Machine learning algorithm enabled computerized diagnosis. Pre-clinical analysis with patient samples showed diagnosis sensitivity and specificity near 100%. Cross reactivity test showed that the kit is capable of differentiation of COVID-19 from Human Coronavirus 229E, Human Coronavirus OC43, Influenza, and Respiratory Syncytial Virus with near 100% accuracy. The ability of QT100Dx diagnosis COVID-19 virus has been demonstrated with preclinical validation and a prototype has been built in collaboration with our industrial partner. The object of this project is to develop a new function, namely, antibody quantitative analysis from saliva and blood plasma. While quantitation of antibody IgG is used to assess past infections and vaccine effectiveness, quantitative analysis of antibody IgM finds potentials in assisting early diagnosis of COVID-19 infection. The success of this research will expand the clinical utility of QT100Dx and make the kit value-added and market competitive.
Program
Alliance Grants
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
563655-2021
Name nom
Venkatakrishnan, Krishnan
Department département
Mechanical and Industrial Engineering
Organization id
43
Institution établissement
Ryerson University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2021
Award amount
30000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
518
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Medical equipment and apparatus
Area of application fr
Appareils et instruments médicaux
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Installment
inst:1
Partie
1
Nb partie
1
Application title
Portable Raman Analyzer for point-of-care rapid analysis of COVID-19 antibody
Keyword
NSERC
Application summary
Rapid diagnosis of COVID-19 infection is critical for the prevention of disease spread. Our research team developed a point-of-care kit, QT100DxTM, which provides test result 2 minutes after sample preparation and can be used by non-technical personal in a non-lab setting, particularly suitable for mass screening at congregated settings. The kit analyzes both unprocessed raw saliva and blood plasma. The QT100Dx simultaneously detects multiple key essential biomarkers involved in constructing the absolute virus and immune response signals (antibodies) rising in patients due to COVID-19 infection from a very minimal salivary sample of 10 ul. The kit detection sensitivity up to 20 viral particles in 1 ml of saliva and 20 ng antibody per mL of blood plasma, far superior to popular PCR assays. Machine learning algorithm enabled computerized diagnosis. Pre-clinical analysis with patient samples showed diagnosis sensitivity and specificity near 100%. Cross reactivity test showed that the kit is capable of differentiation of COVID-19 from Human Coronavirus 229E, Human Coronavirus OC43, Influenza, and Respiratory Syncytial Virus with near 100% accuracy. The ability of QT100Dx diagnosis COVID-19 virus has been demonstrated with preclinical validation and a prototype has been built in collaboration with our industrial partner. The object of this project is to develop a new function, namely, antibody quantitative analysis from saliva and blood plasma. While quantitation of antibody IgG is used to assess past infections and vaccine effectiveness, quantitative analysis of antibody IgM finds potentials in assisting early diagnosis of COVID-19 infection. The success of this research will expand the clinical utility of QT100Dx and make the kit value-added and market competitive.
Ryerson University - $30,000 Grant (2021-22) | Canada Spends